Governments, PE firms, and corporations are all extracting cash from the same households through mechanisms that never appear on a ballot.

Income tax thresholds in the UK have been frozen at their 2021 levels: £12,570 personal allowance, £50,270 higher-rate threshold. They will not move until April 2031 at the earliest. As wages rise with inflation, more income falls into taxable bands. The government collects more without announcing a rate rise. The Institute for Fiscal Studies estimates 1.5 million more people have entered the tax system since 2021, and 700,000 more are now paying 40% tax on part of their income.

If the personal allowance had risen with inflation since 2021, it would sit at roughly £15,750 today, not £12,570. The higher-rate threshold would be near £63,500, not £50,270. A worker on £50,500 — earning just above the frozen line — pays 40% on income that inflation-adjusted thresholds would still tax at 20%. The OBR projects fiscal drag will yield over £55 billion a year by the end of the decade. That is the equivalent of a 4p rise in the basic rate of income tax. No vote required.

Law of the Trap: a trap works because you do not see it while you are walking into it. The freeze is designed to feel invisible. Pay goes up, people feel like they are doing better, and they are — nominally. But a larger slice of every raise goes to HMRC automatically. The framing does the work: no rate rise sounds like good news. The mechanism underneath is the opposite. People are being nudged into higher brackets quietly, during pay negotiations, where they celebrate the gross number and ignore what the frozen threshold just cost them.

From October 1, 2025, any branded or patented drug imported into the United States faces a 100% tariff unless the manufacturer has already broken ground on a US factory. Generic drugs, which account for around 90% of US prescriptions, are exempt. European drugs face a lower 15% rate under a separate deal. The companies that cannot qualify — smaller biotech and mid-sized manufacturers producing in Canada, Mexico, or the Middle East — face the full 100% with no runway to build their way out. There are currently 214 drugs in active shortage in the US.

US pharmaceutical imports totalled approximately $213 billion in 2024. A 100% tariff on branded drugs does not automatically double the shelf price, but it restructures who absorbs the cost. For the uninsured or underinsured American, brand-name drugs that do not qualify for exemptions will become more expensive. One in four Americans already reported not being able to afford a prescribed medication before this tariff. The companies most exposed are small biotechs making specialty and rare disease treatments — not the Pfizers of the world, who already have ground broken. The NHS in the UK also buys from some of these manufacturers, creating indirect UK exposure via supply chain disruption.

Law of the Landlord: whoever controls the infrastructure sets the rent. Here the infrastructure is US market access. The tariff does not hurt Pfizer or Novartis — they already have US factories or have committed to building them. It hurts the firms that cannot pay the entry fee, which is a billion-dollar construction project. The policy is framed publicly as bringing jobs home and cutting drug prices. Underneath it is a mechanism that consolidates market power with the companies large enough to have already built the moat. People hear 'lower drug prices' and feel relief. The small print is a carve-out for everyone big enough to afford the carve-out.

Private equity firms own companies they cannot sell. The IPO market is slow. Acquisition activity has stalled. Rather than wait, PE firms are using a mechanism called a dividend recapitalisation: the portfolio company borrows money at high interest, then pays that borrowed cash directly to the PE fund as a dividend. The company keeps the debt. The fund keeps the cash. In 2025, this totalled $94 billion in the US alone, a record, according to Moody's Ratings. In Europe, the Middle East and Africa, Moody's now estimates buyout firms have a further €41 billion in borrowing headroom before ratings would be threatened. The engine is still running.

Know this: a dividend recapitalisation means a company you might work for, bank with, or whose bonds sit inside your pension fund has just taken on extra debt — not to build anything, not to hire anyone, but to pay its private equity owner a cash dividend while it waits for a buyer. Moody's notes the 2025 total was more than five times the combined 2022–2023 figure. The companies most used for this are in business services, software, and IT. Your pension fund, if it holds leveraged loan exposure or private credit, is the lender. The PE firm is the recipient. The portfolio company is the collateral.

Law of the Narcissist: the narcissist extracts value from the host while presenting the relationship as mutually beneficial. PE firms describe dividend recaps as returning capital to investors, liquidity management, and financial engineering. What Moody's actually says is that sponsors are prioritising investor distributions over long-term credit health. The company gets more debt, more interest expense, less capacity to invest, and a weaker balance sheet. The fund gets cash. People inside these portfolio companies — employees, suppliers, creditors — absorb the risk that the fund has already been paid to not carry.